ESC 365 - Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy

ESC Professional Premium Access

Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy

Session: Contemporary management of hypertrophic cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor D. Bataiosu (Zurich, CH)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Dana Roxana Bataiosu

University Hospital Zurich, Zurich (Switzerland)

1 follower

5 more presentations in this session

Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)

Speaker: Doctor M. Tafelmeier (Regensburg, DE)

Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms N. Felix (Cajazeiras, BR)

Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry

Speaker: Doctor N. Maurizi (Lausanne, CH)

The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis

Speaker: Miss S. Lyu (Beijing, CN)

Access the full session

Contemporary management of hypertrophic cardiomyopathy

Speakers: Doctor D. Bataiosu, Doctor P. Garcia-Pavia, Doctor M. Tafelmeier, Ms N. Felix, Doctor N. Maurizi...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by